Helicobacter pylori: Gastric Cancer and Extragastric Intestinal Malignancies

Helicobacter

Volumn 17, Issue SUPPL.1, 2012, Pages 30-35

  Selgrad, Michael ^a   Bornschein, Jan ^a   Rokkas, Theodore ^b   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Atrophic gastritis; Colorectal cancer; Gastric cancer; Pepsinogen EMR

Indexed keywords

BACTERIUM ANTIBODY; CAPECITABINE; CETUXIMAB; DOCETAXEL; FLUOROURACIL; GASTRIN; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEPSINOGEN I; PEPSINOGEN II; PLATINUM; SUNITINIB;

ANEMIA; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL PROTOCOL; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FATIGUE; GASTRIN BLOOD LEVEL; GENETIC ASSOCIATION; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; INFECTION CONTROL; MORBIDITY; NAUSEA; NEUTROPENIA; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; SEROLOGY; STOMACH CANCER; STOMACH MUCOSA; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR LOCALIZATION; VOMITING;

ANIMALS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL DISEASES; INTESTINES; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

EID: 84866179427     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00980.x     Document Type: Review

References (53)

1. Malfertheiner P, Megraud F, O'MoraCA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
2. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
3. Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449-56.
4. Annibale B, Aprile MR, D'ambra G, Caruana P, Bordi C, Delle FG. Cure of Helicobacter pylori infection atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000;14:625-34.
5. Islami F, Sheikhattari P, Ren JS, Kamangar F. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma-a systematic review and meta-analysis. Ann Oncol 2011;22:754-60.
6. Kodama M, Murakami K, Okimoto T, Abe T, Nakagawa Y, Mizukami K, et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia long-term observation. Digestion 2012;85:126-30.
7. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006;9:245-53.
8. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006;163:629-37.
9. Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result a rural Chinese community. Int J Cancer 2012;130:1614-9.
10. Shikata K, Ninomiya T, Yonemoto K, Ikeda F, Hata J, Doi Y, et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol 2012;47:669-75.
11. Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Shakeri R, Persson EC, Islami F, et al. Accuracy and cut-off values of pepsinogens I, II and gastr17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS ONE 2011;6:e26957.
12. Abnet CC, Zheng W, Ye W, Kamangar F, Ji BT, Persson C, et al. Plasma pepsinogens, antibodies against Helicobacter pylori, and risk of gastric cancer the Shanghai Women's Health Study Cohort. Br J Cancer 2011;104:1511-6.
13. Lomba-Viana R, Nis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer a European country. Eur J Gastroenterol Hepatol 2012;24:37-41.
14. Shimoyama T, Aoki M, Sasaki Y, Matsuzaka M, Nakaji S, Fukuda S. ABC screening for gastric cancer is not applicable a Japanese population with high prevalence of atrophic gastritis. Gastric Cancer 2012;15:331-4. [Epub ahead of print].
15. BornscheJ, Selgrad M, Wex T, Kuester D, Malfertheiner P. Serological assessment of gastric mucosal atrophy gastric cancer. BMC Gastroenterol 2012;12:10.
16. Agreus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di MF, Leja M, et al. Rationale diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-47.
17. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94.
18. Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T, et al. Identification of gastric cancer risk markers that are informative individuals with past H. pylori infection. Gastric Cancer 2012; press. [Epub ahead of print].
19. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Fukuda K, et al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period. Surg Endosc 2012;26:72-8.
20. Han JS, Jang JS, Choi SR, Kwon HC, Kim MC, Jeong JS, et al. A study of metachronous cancer after endoscopic resection of early gastric cancer. Scand J Gastroenterol 2011;46:1099-104.
21. Toyokawa T, Fujita I, Morikawa T, Okamoto A, Miyasaka R, Watanabe K, et al. Clinical outcomes of ESD for early gastric neoplasms elderly patients. Eur J ClInvest 2011;41:474-8.
22. Ahn JY, Jung HY, Choi KD, Choi JY, Kim MY, Lee JH, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011;74:485-93.
23. Vinuela EF, Gonen M, Brennan MF, Coit DG, Strong VE. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg 2012;255:446-56.
24. Ohtani H, Tamamori Y, Noguchi K, Azuma T, Fujimoto S, Oba H, et al. Meta-analysis of laparoscopy-assisted and open distal gastrectomy for gastric cancer. J Surg Res 2011;171:479-85.
25. Zorcolo L, Rosman AS, Pisano M, Marcon F, Restivo A, Nigri GR, et al. A meta-analysis of prospective randomized trials comparing minimally invasive and open distal gastrectomy for cancer. J Surg Oncol 2011;104:544-51.
26. Han JH, Lee HJ, Suh YS, Han DS, Kong SH, Yang HK. Laparoscopy-assisted distal gastrectomy compared to open distal gastrectomy early gastric cancer. Dig Surg 2011;28:245-51.
27. Zhao Y, Yu P, Hao Y, Qian F, Tang B, Shi Y, et al. Comparison of outcomes for laparoscopically assisted and open radical distal gastrectomy with lymphadenectomy for advanced gastric cancer. Surg Endosc 2011;25:2960-6.
28. Sica GS, Iaculli E, Biancone L, Di CS, Scaramuzzo R, Fiorani C, et al. Comparative study of laparoscopic vs open gastrectomy gastric cancer management. World J Gastroenterol 2011;17:4602-6.
29. Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park do J, et al. Survival benefit of gastrectomy +/- metastasectomy patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer 2011;14:130-8.
30. Hultman B, Lundkvist J, Glimelius B, Nygren P, Mahteme H. Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy peritoneal carcinomatosis from gastric cancer. Acta Oncol 2012;51:112-21.
31. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011;254:684-93.
32. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J ClOncol 2011;29:1715-21.
33. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatfor gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-21.
34. Katayama H, Ito S, Sano T, Takahari D, Mizusawa J, Boku N, et al. A Phase II study of systemic chemotherapy with Docetaxel, Cisplatin, and S-1 (DCS) Followed by surgery gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group Study JCOG1002. Jpn J ClOncol 2012;42:556-9.
35. Shridhar R, Dombi GW, FinkelsteSE, Meredith KL, Hoffe SE. Improved survival patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2011;117:3908-16.
36. Woll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grunberger B, et al. Oxaliplatin, irinotecan and cetuximab advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). Anticancer Res 2011;31:4439-43.
37. Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, Ruan DY, et al. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) patients with advanced gastric cancer. Am J ClOncol 2011;34:555-60.
38. Kos FT, Uncu D, Ozdemir N, Budakoglu B, Odabas H, Abali H, et al. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens the first-line treatment of metastatic gastric cancer. Chemotherapy 2011;57:230-5.
39. Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, et al. Docetaxel plus oxaliplatcombination with capecitabine as first-line treatment for advanced gastric cancer. Oncology 2011;80:359-65.
40. Takeyoshi I, Makita F, Iwazaki S, Ishikawa H, Kakinuma S, Sato Y, et al. Weekly paclitaxel combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites. Anticancer Res 2011;31:4625-30.
41. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011;47:1511-20.
42. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, et al. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS ONE 2011;6:e24662.
43. Meucci G, Tatarella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, et al. High prevalence of Helicobacter pylori infection patients with colonic adenomas and carcinomas. J ClGastroenterol 1997;25:605-7.
44. Shmuely H, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, et al. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol 2001;96:3406-10.
45. Siddheshwar RK, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of Helicobacter pylori patients with colorectal polyps and colorectal carcinoma. Am J Gastroenterol 2001;96:84-8.
46. Konturek PC, Konturek SJ, Bielanski W, Karczewska E, Pierzchalski P, Duda A, et al. Role of gastrgastric cancerogenesis Helicobacter pylori infected humans. J Physiol Pharmacol 1999;50:857-73.
47. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastr- active participant or bystander gastric carcinogenesis? Nat Rev Cancer 2006;6:936-46.
48. Niv Y. Gastrand colorectal neoplasia: cause and effect. Digestion 2006;74:40-1.
49. Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: a meta-analysis. Helicobacter 2006;11:75-80.
50. Zhao YS, Wang F, Chang D, Han B, You DY. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer. Int J Colorectal Dis 2008;23:875-82.
51. Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study Germany. Am J Epidemiol 2012;175:441-50.
52. Inoue I, Mukoubayashi C, Yoshimura N, Niwa T, Deguchi H, Watanabe M, et al. Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a population-based case-control study. Int J Cancer 2011;129:2704-11.
53. Hong SN, Lee SM, Kim JH, Lee TY, Kim JH, Choe WH, et al. Helicobacter pylori infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. Dig Dis Sci 2012; press. [Epub ahead of print].